

Supplementary Table 5. 2^a sensitivity analysis. Regression models for all the diseases together comparing patients who discontinued therapy according to clinical remission vs patients who continue

		Bivariable model			Multivariable model		
		Crude OR	95% CI	P value	Adjusted OR	95% CI	P value
Female sex		0.66	(0.42-1.04)	0.074	0.73	(0.43-1.25)	0.255
Age at onset		0.99	(0.97-1.00)	0.071	1.01	(0.99-1.03)	0.482
Disease (ref RA)	AS	1.53	(0.84-2.78)	0.161	1.15	(0.53-2.48)	0.731
	PsA	3.04	(1.82-5.08)	<0.001	2.23	(1.22-4.10)	0.010
TNF-i (ref remaining treatments)		3.53	(1.69-7.39)	0.001	1.64	(0.70-3.86)	0.259
Smoking (ref smoker)	Non-smoker	2.50	(1.23-5.05)	0.011	2.62	(1.27-5.42)	0.009
	Ex-smoker	0.46	(0.10-2.16)	0.325	0.62	(0.13-2.97)	0.550
Second line of treatment (vs first line)		1.04	(0.66-1.63)	0.881	1.71	(1.03-2.84)	0.038
Disease duration		0.95	(0.92-0.99)	0.006	0.94	(0.90-0.98)	0.002
Concomitant csDMARD		0.65	(0.41-1.01)	0.057	0.60	(0.37-1.00)	0.049
Moderate-high activity*		0.66	(0.32-1.37)	0.268			
Time on treatment with the previous biologic agent		1.01	(1.01-1.02)	<0.001	1.01	(1.01-1.02)	<0.001
Year of discontinuation of treatment		0.97	(0.93-1.02)	0.277	0.97	(0.91-1.02)	0.235

Footnote to table 2: OR: odds ratio. 95% CI: 95% confidence interval. TNF-i: tumor necrosis factor alfa inhibitor. RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis. csDMARD: conventional synthetic DMARD.

* High activity: DAS28 \geq 3.2 or BASDAI \geq 4